- Conway PL. Microbial ecology of the human large intestine. Human colonic bacteria; 1995.
2. Jay CM, Bhaskaran S, Rathore S, Waghela SD. Enterotoxigenic 99+ Escherichia coli
attachment to host cell receptors inhibited by recombinant pili protein. Vet Microbiol. 2004;
101: 153-160.
3. Clarke SC. Diarrhoeagenic Escherichia coli an emerging problem. Diagn Microbiol Infect Dis.
2001; 41: 93-98.
4. Heuvelink A, Bleumink B, Van den Biggelaar F, Te Giffel M, Beumer R, De Boer E.
Occurrence and survival of verocytotoxin-producing Escherichia coli O157 in raw cow's milk
in The Netherlands. J Food Prot. 1998; 61: 1597-1601.
5. Walker T. Microbiology. Saunders Company, Philadelphia. 1998.
6. armali MA. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev. 1989;
2: 15-38.
7. Hara- udo J. Flourogenic and chromogenic media, the rapid technique for isolation of V.
cholera. J. Appl. And Eviron. Mic. 2003; 67: 5819-5823.
8. Schroeder CM, Cuiwei Z, Chitrita D, Jocelyn T, Shaohua Z, White DG. Antimicrobial
Resistance of Escherichia coli O157 Isolated from Humans, Cattle, Swine, and Food. Appl
Environ Microbiol. 2002; 68(2): 576–581.
9. Salyers AA. Bacterial pathogenesis: a molecular approach, ASM press Washington. 1994.
10. Serra-Moreno R, Jofre J, Muniesa M. The CI Repressors of Shiga Toxin-Converting
Prophages Are Involved in Coinfection of Escherichia coli Strains, Which Causes a Down
Regulation in the Production of Shiga Toxin. J Bacteriol. 2008; 190(13): 4722–4735.
11. Maleki H, Salmanian AH, Amani J, ordenaiej A, Jafari M. Production of Bivalent Protein
EspA-Tir from Escherichia coli O157:H7 in Tobacco (Nicotiana tobbacum). Crop Biotech.
2013; 5: 1-9. [in Persian]
12. Lima M, dos Santos SA, Rodrigues JM, Silva CL. Vaccine adjuvant: it makes the difference.
Vaccine. 2004; 22: 2374-2379.
13. Aguilar J. Vaccine adjuvants revisited. Vaccine. 2007; 25: 3752-3762.
14. Mac ichan ML, O'Hagan DT, Singh M. Recent developments in adjuvants for vaccines
against infectious diseases. Biomol Eng. 2001; 18: 69-85.
15. Alving CR. Design and selection of vaccine adjuvants: animal models and human trials.
Vaccine. 2002; 20: 56-64.
16. Rojo-Montejo S, Collantes-Fernández S, Regidor-Cerrillo E, Rodríguez-Bertos J, Prenafeta A,
Gomez-Bautista A. Influence of adjuvant and antigen dose on protection induced by an
inactivated whole vaccine against Neospora caninum infection in mice. Vet Parasitol. 2001;
175: 220-229.
17. Doavi T, Mousavi SL, amali M, Amani J, Ramandi MF. Chitosan-based intranasal vaccine
against Escherichia coli O157: H7. IBj. 2016; 20(2): 97. [in Persian]
18. Meng J., Zhao Sh, Doyle MP, Mitchell SE, resovich S. Polymerase chain reaction for
detecting Escherichia coli O157:H7. Int J Food Microbiol. 1996; 32: 103-113.
19. Namdar N, argar M, Tahamtan Y, Hosseini MH. Antagonistic effects of bifidobacterium spp.
in decrease of cytopathic effects of Verotoxin-producing Escherichia coli. JMW. 2013; 5:
94-104. [In Persian].
20. Tahamtan Y, Alimohamadi N. Evaluation of three dilutions of E. coli antigen in
immunogenicity in balb/c mice. Vet Res Biol. 2017; 117: 40-49. [In Persian].
21. Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol
Immunol. 1991; 28: 279-284.
22. Hasani SH, Hosseini Jazani N, Shahabi Sh, aramati SA. Evalution of the effect of ICI118,
155, A beta adrenoreceptor antagonsit, and allum, as adjuvantes for increasing the protection
of vaccination against almonella typhimurium. Urmia medical journal. 2014; 24: 851-861.
[In Persian].
23. Figueiredo H, Lage AP, Pereira Júnior FN, Leite RC. Passive immunity in cattle against
enterotoxigenic Escherichia coli: serologic evaluation of a bacterin containing 99 and F41
fimbriae in colostrum of vaccinated females and calf serum. Arq Bras Med Vet Zootec. 2004;
56: 425-432.
24. Jazani NH, Parsania S, Sohrabpour M, Mazloomi E, arimzad M, Shahabi Sh. Naloxone and
alum synergistically augment adjuvant activities of each other in a mouse vaccine model of
almonella typhimurium infection. Immunobiology. 2011; 216: 744-751.
25. Raman VS,. Reed SG, Malcolm MS, Christopher B, Matlashewski G. Adjuvants for
eishmania vaccines: from models to clinical application. Front Immunol. 2012; 3: 144.
26. Leotta GA, Miliwebsky ES, Chinen I, Espinosa EM, Azzopardi , Tennant SM.
Characterisation of Shiga toxin-producing Escherichia coli O157 strains isolated from humans
in Argentina. BMC Microbiol. 2008; 8: 46.
27. halesi R, Salimian J, Nazarian SH, Ehsaei Z, Rahimi AA, Amini N. Production and
purification of heat-labile toxin of enterotoxigenic Escherichia coli and its detection by GM1
gangelioside receptor-ELISA based method. AMUJ. 2012; 15: 35-42. [In Persian]
28. Ebadi V, Ebrahimi F, Hajizadeh A, Tarverdizadeh Y, Bakhshi M. Designing a Recombinant
Vaccine containing three bacterial proteins of EHEC, ETEC, and Shigella Dysentery Antigens
in E. coli and Evaluation of its Humoral Immunity in Mic. J Mazandaran Univ Med Sci. 2018;
27: 1 – 16. [in Persian]
|
